Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (Nasdaq: LFMD) is a virtual primary care and pharmacy company whose news flow centers on telehealth expansion, clinical program development, strategic collaborations, and capital markets activity. As a provider of virtual healthcare services across more than 200 conditions, LifeMD regularly issues updates on its weight management, women’s health, men’s health, behavioral health, and primary care offerings, as well as on its pharmacy and compounding pharmacy capabilities.
News about LifeMD often highlights clinical and commercial partnerships, particularly in obesity and metabolic health. The company has announced an expanded collaboration with Novo Nordisk, under which LifeMD is recognized as a telehealth partner offering FDA-approved GLP‑1 therapies such as Wegovy and Ozempic. Press releases describe new product availability, including the Wegovy oral pill, and cash-pay pricing initiatives designed to broaden access to branded GLP‑1 medications through LifeMD’s virtual weight management programs.
Investors and observers can also expect financial and corporate updates in LifeMD’s news stream. These include quarterly earnings releases, segment performance commentary, and disclosures about strategic transactions such as the divestiture of its majority interest in WorkSimpli Software LLC. The company’s transition into a pure-play virtual care and pharmacy platform, along with its efforts to strengthen its balance sheet, are recurring themes in management commentary.
Additional news items cover capital structure and governance developments, such as the authorization of dividends on the company’s 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) and the establishment of a senior secured revolving credit facility with Citizens Bank, N.A. Regulatory and reporting updates, including Forms 8‑K and notifications of late filings related to financial statement adjustments, also appear in the company’s announcements.
For those following LFMD, this news page provides a centralized view of LifeMD’s earnings reports, clinical program launches, partnership expansions, financing arrangements, and regulatory disclosures, offering context on how the company is evolving its virtual care and pharmacy platform over time.
Medifast (NYSE: MED) reported Q3 2024 financial results with revenue of $140.2 million, down 40.6% from $235.9 million in Q3 2023. The company had 30,000 active earning OPTAVIA coaches, a 36.3% decrease from 47,100 in the previous year. Net income was $1.1 million ($0.10 per diluted share), compared to $23.1 million ($2.12 per diluted share) in Q3 2023. The company maintains a strong balance sheet with $170.0 million in cash and no debt. For Q4 2024, Medifast expects revenue between $100-120 million and projects a diluted loss per share of $0.10 to $0.65.
LifeMD (Nasdaq: LFMD), a virtual primary care services provider, has scheduled its third quarter 2024 financial results announcement for November 7, 2024, after U.S. market close. The company will host a conference call at 4:30 p.m. Eastern time, accessible via toll-free (800-717-1738) and international (646-307-1865) dial-in numbers, with conference ID 73461.
Medifast (NYSE: MED), the health and wellness company behind the OPTAVIA® lifestyle solution, has announced it will release its third quarter 2024 financial results on Monday, November 4, 2024, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results.
Key participants in the call will include Dan Chard, Chairman and CEO, and Jim Maloney, CFO. The call will be broadcast live on Medifast's Investor Relations website and archived for access until February 4, 2025. Telephone access is available by dialing (201) 389-0879, with a playback option available from 8:30 p.m. ET, November 4, through November 11, 2024, using access code 13749320.
LifeMD, Inc. (Nasdaq: LFMD), a leading virtual primary care services provider, has announced a quarterly cash dividend for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The dividend, authorized by the company's Board of Directors, amounts to $0.5546875 per share. Shareholders of record as of the close of business on October 4, 2024, will receive the dividend payment on October 15, 2024. This announcement demonstrates LifeMD's commitment to providing returns to its preferred stockholders.
LifeMD (Nasdaq: LFMD) has announced major enhancements to its weight management program, expanding patient access to branded GLP-1 therapies and introducing new treatment options. The company has implemented a real-time electronic benefit verification program and partnered with an AI-powered platform to optimize prior authorization submissions. These improvements are estimated to increase LifeMD's addressable weight loss market by 15%.
Key advancements include:
- Integration of at-home, self-collection laboratory testing services
- Launch of a personalized therapy alternative to GLP-1 medications
- Improved pharmacy benefits infrastructure
Over the past 30 days, 38% of patients providing insurance information received affordable coverage for branded GLP-1 medication, with expectations to exceed 50% soon.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has announced its participation in three major investor conferences in September 2024. The company's management will attend:
1. H.C. Wainwright 26th Annual Global Investment Conference (Sept. 9-11) in New York, featuring a corporate presentation on Sept. 9 at 12:00 p.m. ET.
2. TD Cowen 9th Annual FutureHealth Conference (Sept. 10) in New York, participating in a panel discussion at 2:20 p.m. ET.
3. Cantor Fitzgerald Global Healthcare Conference (Sept. 17-19) in New York, with a fireside chat on Sept. 18 at 8:35 a.m. ET.
At these events, LifeMD's management will engage in one-on-one meetings with investors, showcasing the company's progress and future prospects in the virtual healthcare sector.
LifeMD (LFMD) reported strong Q2 2024 results, with revenue increasing 41% year-over-year to $50.7 million. Telehealth revenue grew 67%, and the segment achieved profitability one quarter ahead of guidance with adjusted EBITDA of $820,000. Key highlights include:
- Telehealth active subscribers increased 32% to 254,000
- Weight management subscribers exceeded 60,000
- Gross margin expanded to 90%
- Adjusted EBITDA increased 44% to $2.5 million
- Cash position of $35.7 million as of June 30, 2024
The company raised its 2024 telehealth revenue guidance to $150 million and introduced telehealth adjusted EBITDA guidance of $3-4 million. However, due to WorkSimpli's underperformance, consolidated adjusted EBITDA guidance was revised to $13-15 million.
Medifast (NYSE: MED) reported Q2 2024 financial results, showing a 43.1% decrease in revenue to $168.6 million. The company experienced a net loss of $8.2 million, or $0.75 per diluted share. Key metrics include:
- Revenue per active earning Coach: $4,972
- Independent active earning OPTAVIA Coaches: 33,900
- Non-GAAP adjusted net income: $10.1 million
- Non-GAAP adjusted EPS: $0.92
- Cash and equivalents: $163.5 million with zero debt
Medifast is transforming its business for long-term growth, focusing on new customer acquisition and expanding its health and wellness offerings. The company's outlook for Q3 2024 projects revenue between $125-$145 million and a diluted loss per share of $0.05 to $0.70.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has announced it will release its Q2 2024 financial results on August 7, 2024, after U.S. financial markets close. The company will host a conference call at 4:30 p.m. Eastern time on the same day to discuss the results. Investors can access the call via toll-free (1-800-245-3047) or international (1-203-518-9765) dial-in numbers, using the conference ID: LIFEMD. A live and archived webcast of the call will also be available.
LifeMD (Nasdaq: LFMD), a leading virtual primary care provider, has announced its participation in two major investor conferences in August 2024. The company will attend the KeyBanc Capital Markets Technology Leadership Forum from August 4-6 in Vail, Colorado, where management will engage in a fireside chat on August 5th and conduct one-on-one investor meetings.
Additionally, LifeMD will be present at the Canaccord Genuity 44th Annual Growth Conference from August 13-15 at the InterContinental Boston hotel. During this event, the management team will deliver a corporate overview on August 14th and hold individual meetings with investors. These conferences provide LifeMD with valuable opportunities to showcase its business model and growth strategies to potential investors and industry analysts.
FAQ
What is the current stock price of Lifemd (LFMD)?
What is the market cap of Lifemd (LFMD)?
